News

Muscular and Neuromuscular Diseases

PepGen Goes Public in $108 Million IPO

Edward Kim | Equities.com |

The company is developing treatments for serious genetic diseases, with an initial focus on neuromuscular diseases.


Sponsored Financial Content

Market Movers